TITLE:
Effectiveness and Safety of Enbrel (Etanercept) in Rheumatoid Arthritis Subjects Who Have Failed Remicade (Infliximab)

CONDITION:
Rheumatoid Arthritis

INTERVENTION:
Etanercept

SUMMARY:

      The purpose of this study is to evaluate the proportion of Rheumatoid Arthritis (RA)
      subjects achieving a "good" or "moderate" DAS28 response (EULAR28 criteria) at Week 16 with
      etanercept 50 mg subcutaneously (SC) once weekly in patients who have failed infliximab.
    

DETAILED DESCRIPTION:
NONE

ELIGIBILITY:
Gender: All
Age: 18 Years to N/A
Criteria:

        Inclusion Criteria:

          -  Adults with RA (ACR criteria) for greater than or equal to 6 months

          -  Infliximab treatment for at least 18 weeks

          -  Infliximab infusion prior to screening at an increased dosing regimen: 5 mg/kg every
             4-8 weeks (dose), OR, 3 mg/kg every 4-6 weeks (frequency)

          -  Failing infliximab defined by ALL of the following at screening and baseline visit:
             Disease Activity Score (DAS 28) greater than or equal to 4.5, greater than or equal
             to 5 swollen joints, greater than or equal to 5 tender joints

          -  Subjects must be receiving stable methotrexate (MTX), at a dose of greater than or
             equal to 10 mg/week at least 10 weeks prior to screening

          -  Stable disease modifying anti-rheumatic drugs (DMARD) therapy (including
             sulfasalazine, hydroxychloroquine), greater than or equal to 8 weeks prior to
             screening

          -  Stable dose corticosteroids, less than 10 mg/day at greater than or equal to 4 weeks
             prior to screening

          -  Stable dose of non-steroidal anti-inflammatory drugs (NSAIDs) greater than or equal
             to 1 week prior to screening

        Exclusion Criteria:

          -  ACR functional class IV - Prior treatment with etanercept

          -  Receipt of any investigational drug/biologic within 28 days of study drug initiation

          -  Active infection or predisposition to infection

          -  Elective surgery planned during study period

          -  Intra-articular, soft tissue, or intramuscular corticosteroid injections during 4
             weeks prior to screening

          -  Contraindications to etanercept as defined in the package insert

          -  Severe co-morbidities: History of cancer within 5 years; Diagnosis of class III or IV
             congestive heart failure (CHF); Uncontrolled hypertension (HTN); CNS-demyelinating
             events suggestive of multiple sclerosis (MS); Known HIV-positive status;
             Oxygen-dependent pulmonary status; Chronic hepatitis B or C; Systemic Lupus
             Erythematosus (SLE); Active or prior history of tuberculosis (TB) (or known exposure)
             or positive PPD without adequate TB prophylaxis
      
